919349-69-2

Upstream product

• 5707-04-0 Phenylselenyl chloride 
• 138629-30-8 (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
• 17342-08-4 (S)-Pyroglutaminol 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 34837-55-3 Phenylselenyl bromide 

Downstream Products

• 144564-15-8 4R,5S-1-t-butoxycarbonyl-5-t-butyldiphenylsiloxymethyl-4-(4-chlorphenyl)pyrrolidine-2-one 
• 144564-13-6 4S,5S-1-t-butoxycarbonyl-5-t-butyldiphenylsiloxymethyl-4-phenylpyrrolidine-2-one 
• 144564-16-9 tert-butyl (4S,5S)-4-allyl-5-((tert-butyldiphenylsilyl)oxymethyl)-2-oxopyrrolidine-1-carboxylate 
• 144564-12-5 4S,5S-1-t-butoxycarbonyl-4-butyl-5-t-butyldiphenylsiloxymethylpyrrolidine-2-one 
• 144564-14-7 (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one 
• 144564-10-3 2S,3R-1-t-butoxycarbonyl-3-(4-chlorophenyl)-5-oxo-pyrrolidine-2-carboxylic acid 
• 144564-09-0 4R,5S-1-t-butoxycarbonyl-4-(4-chlorophenyl)-5-hydroxymethyl-pyrrolidine-2-one 
• 78184-72-2 3R-1-t-butoxycarbonylamino-3-(4-chlorophenyl)butanoic acid 
• 144564-11-4 (R)-tert-butyl 4-(4-chlorophenyl)-2-oxopyrrolidine-1-carboxylate 
• 158135-16-1 (4R,5S)-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-4-methylpyrrolidin-2-one 
• 158038-36-9 (5S)-3,4-dihydro-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-4-methylpyrrolidin-2-one 
• 138871-60-0 (4S,5S)-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-4-methylpyrrolidin-2-one 
• 910548-23-1 (3R,4R,5S)-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-3,4-pyrazolinepyrrolidin-2-one 
• 910548-22-0 (2S,3S)-3-methylglutamic acid hydrochloride 

Relevant academic research and scientific papers

STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumours.

Addressing protein-protein interactions with small molecules: A pro-pro dipeptide mimic with a PPII helix conformation as a module for the synthesis of PRD-binding ligands

X marks the spot: The synthetic tricyclic amino acid X (see structure; C gray, H cyan, N blue, O red, double bond yellow) can be incorporated, without loss of binding ability, as a Pro-Pro substitute into two peptides that bind to the proline-rich motif-recognizing domains Fyn-SH3. The dipeptide analogue X, which is locked in a polyproline type II helix conformation, is created by stereoselective introduction of a vinylidene bridge into a diproline unit.

Biosynthesis of the (2S,3R)-3-methyl glutamate residue of nonribosomal lipopeptides

The calcium-dependent antibiotics (CDAs) and daptomycin are therapeutically relevant nonribosomal lipopeptide antibiotics that contain penultimate C-terminal 3-methyl glutamate (3-MeGlu) residues. Comparison with synthetic standards showed that (2S,3R)-co

Synthesis of Homochiral R-Baclofen from S-Glutamic Acid

A streoselective synthesis of R-Baclofen is presented starting from S-pyroglutamic acid derivative 3.The key steps are the 1,4-conjugate addition of Grignard cuprate (p-ClPh)2CuMgCl to 3 and Barton-Decarboxylation of 6e to 7e.